SCE analysis in G2 lymphocyte prematurely condensed chromosomes after exposure to atrazine: the non-dose-dependent increase in homologous recombinational events does not support its genotoxic mode of action.
Several studies have been carried out to evaluate the mutagenic and carcinogenic potential of atrazine, the most prevalent of triazine herbicides classified as a "possible human carcinogen". The majority of these studies have been negative but positive responses have been also reported including mammary tumors in female Sprague-Dawley rats. Sister chromatid exchanges (SCEs) caused by the presence of DNA lesions at the moment of DNA replication have been extensively used for genotoxicity testing, but for non-cytotoxic exposures to atrazine controversial results have been reported. Even though exposures to higher concentrations of atrazine could provide clear evidence for its genotoxicity, conventional SCE analysis at metaphase cells cannot be used because affected cells are delayed in G2-phase and do not proceed to mitosis. As a result, the genotoxic potential of atrazine may have been underestimated. Since clear evidence has been recently reported relating SCEs to homologous recombinational events, we are testing here the hypothesis that high concentrations of atrazine will cause a dose-dependent increase in homologous recombinational events as quantified by the frequency of SCEs analyzed in G2-phase. Towards this goal, a new cytogenetic approach is applied for the analysis of SCEs directly in G2-phase prematurely condensed chromosomes (PCCs). The methodology enables the visualization of SCEs in G2-blocked cells and is based on drug-induced PCCs in cultured lymphocytes. The results obtained for high concentrations of atrazine do not demonstrate a dose-dependent increase in homologous recombinational events. They do not support, therefore, a genotoxic mode of action. However, they suggest that an important part in the variation of SCE frequency reported by different laboratories when conventional SCE analysis is applied after exposure to a certain concentration of atrazine, is due to differences in cell cycle kinetics of cultured lymphocytes, rather than to a true biological variation in the cytogenetic end point used.
Malik
S I
SI
Health Physics & Environmental Hygiene, National Centre for Scientific Research "Demokritos", Athens, Greece.
Terzoudi
G I
GI
Pantelias
G E
GE
D000328:Adult; D001280:Atrazine / Q000494:pharmacology / Q000633:toxicity*; D002503:Centromere / Q000648:ultrastructure; D002877:Chromosomes, Human / Q000187:drug effects* / Q000648:ultrastructure; D003432:Cross-Linking Reagents / Q000494:pharmacology / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D016195:G2 Phase; D006540:Herbicides / Q000494:pharmacology / Q000633:toxicity*; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects* / Q000648:ultrastructure; D008677:Metaphase; D016685:Mitomycin / Q000494:pharmacology / Q000633:toxicity; D008957:Models, Genetic; D011995:Recombination, Genetic / Q000187:drug effects*; D012689:Sequence Homology, Nucleic Acid; D012854:Sister Chromatid Exchange / Q000187:drug effects*
D003432:Cross-Linking Reagents; D006540:Herbicides; D016685:Mitomycin; D001280:Atrazine